Form 4: BioCardia Director Acquires Stock Options

BioCardia, Inc. reports that Director Andrew Scott Blank was granted stock options for 8,000 shares.

Summary

• Andrew Scott Blank, a Director at BioCardia, Inc., was granted stock options on July 6, 2026.
• The options are for 8,000 shares of common stock.
• The exercise price for these options is $1.20 per share.
• These options vest and become exercisable one year from the grant date, provided Mr. Blank remains a service provider.
• Following this transaction, Mr. Blank beneficially owns 23,313 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation event for a director rather than a significant financial or strategic development for the company.

Positives

• Director Andrew Scott Blank has been granted stock options, indicating potential future equity ownership and alignment with company performance.
• The grant of 8,000 stock options suggests confidence in the company's future prospects by management/board.
• The exercise price of $1.20 per share is relatively low, offering significant upside potential if the stock price increases.

Negatives

• The options are subject to vesting, meaning Mr. Blank will not immediately benefit from them.
• The vesting is contingent on continued service, creating a retention requirement.

Risks

• The value of the stock options is entirely dependent on the future performance and stock price of BioCardia, Inc.
• If Mr. Blank ceases to be a service provider before the vesting date, the options will not become exercisable.
• Market volatility and company-specific challenges could prevent the stock price from rising above the exercise price.

Future Outlook

The stock options granted to Andrew Scott Blank are exercisable on or after July 6, 2036, provided he remains a service provider through the one-year vesting period from the grant date.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biotechnology and healthcare sectors to incentivize leadership and align their interests with shareholders, especially for companies focused on development and growth.

Stakeholder Impact

• Shareholders: The grant of options to a director aligns management's interests with shareholders, potentially driving performance. However, dilution could occur if options are exercised.
• Employees: This filing does not directly impact employees, but it reflects standard compensation practices for leadership.
• Management: The options provide a financial incentive for continued service and performance.

Next Steps

• Andrew Scott Blank must continue as a service provider to BioCardia, Inc. through July 6, 2027, for the stock options to vest.
• The stock options will become exercisable on July 6, 2027.
• The stock options expire on July 6, 2036.

Key Dates

Keywords

BioCardia, BCDA, Form 4, Stock Options, Director, Beneficial Ownership, Equity Grant, Vesting, SEC Filing